SYBX Key Statistics, Chart & Performance
The current stock price of SYBX is 1.13 USD. In the past month the price increased by 2.73%. In the past year, price decreased by -22.6%.
SYBX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.23 | 387.94B | ||
| AMGN | AMGEN INC | 14.73 | 173.48B | ||
| GILD | GILEAD SCIENCES INC | 14.88 | 151.16B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.2 | 115.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.81 | 79.53B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 720.89 | 48.57B | ||
| INSM | INSMED INC | N/A | 34.62B | ||
| NTRA | NATERA INC | N/A | 32.43B | ||
| BIIB | BIOGEN INC | 10.79 | 26.50B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.00B | ||
| INCY | INCYTE CORP | 16.3 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.01 | 20.46B |
Related stock screener links
About SYBX
Company Profile
Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. The company is headquartered in Winchester, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2015-09-30. The firm is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The firm's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The firm designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Company Info
SYNLOGIC INC
Po Box 30
Winchester MASSACHUSETTS 02142 US
CEO: Aoife Brennan
Employees: 1
Phone: 16176592802
SYNLOGIC INC / SYBX FAQ
What does SYBX do?
Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. The company is headquartered in Winchester, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2015-09-30. The firm is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The firm's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The firm designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
What is the current price of SYBX stock?
The current stock price of SYBX is 1.13 USD.
Does SYNLOGIC INC pay dividends?
SYBX does not pay a dividend.
What is the ChartMill rating of SYNLOGIC INC stock?
SYBX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of SYBX stock?
SYNLOGIC INC (SYBX) has a market capitalization of 13.22M USD. This makes SYBX a Nano Cap stock.
What is the ownership structure of SYNLOGIC INC (SYBX)?
You can find the ownership structure of SYNLOGIC INC (SYBX) on the Ownership tab.
SYBX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SYBX. When comparing the yearly performance of all stocks, SYBX is a bad performer in the overall market: 89.9% of all stocks are doing better.
SYBX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SYBX. While SYBX seems to be doing ok healthwise, there are quite some concerns on its profitability.
SYBX Financial Highlights
Over the last trailing twelve months SYBX reported a non-GAAP Earnings per Share(EPS) of -2.51. The EPS increased by 76.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.49% | ||
| ROE | -31.25% | ||
| Debt/Equity | 0 |
SYBX Forecast & Estimates
6 analysts have analysed SYBX and the average price target is 1.02 USD. This implies a price decrease of -9.73% is expected in the next year compared to the current price of 1.13.